116 related articles for article (PubMed ID: 1707034)
1. Hodgkin's disease in adults in Saudi Arabia. Clinical features, prognostic factors and an analysis of therapy. Outcome of combination chemotherapy only, for both localized and advanced disease.
al-Idrissi HY; Ibrahim EM
Int J Cancer; 1991 Apr; 47(6):822-6. PubMed ID: 1707034
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
Straus DJ; Gaynor JJ; Myers J; Merke DP; Caravelli J; Chapman D; Yahalom J; Clarkson BD
J Clin Oncol; 1990 Jul; 8(7):1173-86. PubMed ID: 1694235
[TBL] [Abstract][Full Text] [Related]
3. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience.
Chim CS; Kwong YL; Lie AK; Lee CK; Ho FC; Liang R
Am J Hematol; 1999 Jul; 61(3):159-63. PubMed ID: 10398307
[TBL] [Abstract][Full Text] [Related]
4. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
[TBL] [Abstract][Full Text] [Related]
5. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).
Radman I; Basić N; Labar B; Kovacević J; Aurer I; Bogdanić V; Zupancić-Salek S; Nemet D; Jakić-Razumović J; Mrsić M; Santek F; Grgić-Markulin L; Boban D
Ann Oncol; 2002 Oct; 13(10):1650-5. PubMed ID: 12377656
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
8. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
[TBL] [Abstract][Full Text] [Related]
9. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal BG; Marcus R; Brecher M; Ternberg J; Behm FG; Cantor A; Wharam M; Chauvenet A
J Clin Oncol; 1991 Sep; 9(9):1591-8. PubMed ID: 1714950
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.
Harker WG; Kushlan P; Rosenberg SA
Ann Intern Med; 1984 Oct; 101(4):440-6. PubMed ID: 6206757
[TBL] [Abstract][Full Text] [Related]
12. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
13. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
Tannir N; Hagemeister F; Velasquez W; Cabanillas F
J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
[TBL] [Abstract][Full Text] [Related]
15. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
16. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
17. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
[TBL] [Abstract][Full Text] [Related]
19. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
